Delayed enhancement of subendocardial infarcted myocardium with gadobenate dimeglumine: a paradoxical effect--is a double dose too much?

[1]  C. Catalano,et al.  Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. , 2005, Radiology.

[2]  J. Barkhausen,et al.  Myocardial infarct: depiction with contrast-enhanced MR imaging--comparison of gadopentetate and gadobenate. , 2005, Radiology.

[3]  Alessandro Carriero,et al.  Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity. , 2005, Radiology.

[4]  M. Prokop,et al.  Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. , 2005, Radiology.

[5]  P. Fries,et al.  MultiHance in cardiac magnetic resonance imaging , 2004, European radiology.

[6]  Eckart Fleck,et al.  Magnetic Resonance Low-Dose Dobutamine Test Is Superior to Scar Quantification for the Prediction of Functional Recovery , 2004, Circulation.

[7]  M. Knopp,et al.  Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. , 2004, Radiology.

[8]  Olga Bondarenko,et al.  Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. , 2003, Journal of the American College of Cardiology.

[9]  J. Schulz-Menger,et al.  Cardiovascular magnetic resonance of acute myocardial infarction at a very early stage. , 2003, Journal of the American College of Cardiology.

[10]  Martin Requardt,et al.  Contrast‐enhanced MR angiography of the run‐off vasculature: Intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine , 2003, Journal of magnetic resonance imaging : JMRI.

[11]  Nicole Heussen,et al.  Myocardial viability in chronic ischemic heart disease: comparison of contrast-enhanced magnetic resonance imaging with (18)F-fluorodeoxyglucose positron emission tomography. , 2003, Journal of the American College of Cardiology.

[12]  E. Rummeny,et al.  Low-Dose Gadobenate Dimeglumine Versus Standard Dose Gadopentetate Dimeglumine for Contrast-Enhanced Magnetic Resonance Imaging of the Liver: An Intra-Individual Crossover Comparison , 2003, Investigative radiology.

[13]  J. Debatin,et al.  Intraindividual Comparison of Gadopentetate Dimeglumine, Gadobenate Dimeglumine, and Gadobutrol for Pelvic 3D Magnetic Resonance Angiography , 2003, Investigative radiology.

[14]  M. Völk,et al.  Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. , 2001, Radiology.

[15]  O. Simonetti,et al.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. , 2000, The New England journal of medicine.

[16]  M. Kirchin,et al.  Gadobenate dimeglumine (Gd-BOPTA). An overview. , 1998, Investigative radiology.

[17]  B. Jenkins,et al.  Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. , 1997, Investigative radiology.